Compositions and formulations for hair treatment are provided herein. Methods for hair treatment, such as methods for preventing or treating hair loss or hair thinning, are also provided herein. The methods may promote hair growth, hair restoration or hair thickening, or increase hair density or hair growth rate.

The present disclosure provides compositions and methods of treating a viral infection comprising administering an antiviral cocktail that includes a protease inhibitor and an anticoagulant agent, anti-inflammatory agent and/or an antiviral agent for conjoint administration to a subject.

The present disclosure provides compositions and methods of treating a viral infection comprising administering an antiviral cocktail that includes a protease inhibitor and an anticoagulant agent, anti-inflammatory agent and/or an antiviral agent for conjoint administration to a subject.

The present disclosure provides compositions and methods of treating a viral infection comprising administering an antiviral cocktail that includes a protease inhibitor and an anticoagulant agent, anti-inflammatory agent and/or an antiviral agent for conjoint administration to a subject.

A method for producing at least one microneedle containing a vaccine for transdermal delivery of the vaccine to a patient includes preparing microparticles or nanoparticles of encapsulated vaccine by preparing a solution comprising a vaccine antigen and a biocompatible polymer matrix; and spray drying the solution to form the microparticles or nanoparticles. The method includes the further steps of preparing a film composition including at least one pre-polymer solution; preparing a suspension comprising the microparticles or nanoparticles and the film composition; loading the suspension into a 3D printer; printing, via the 3D printer, at least one microneedle made from the suspension; and, converting the pre-polymer solution into a cross-linked biopolymer by exposing the at least one microneedle to UV light. Also disclosed are microneedles containing a vaccine for transdermal delivery.

A method for producing at least one microneedle containing a vaccine for transdermal delivery of the vaccine to a patient includes preparing microparticles or nanoparticles of encapsulated vaccine by preparing a solution comprising a vaccine antigen and a biocompatible polymer matrix; and spray drying the solution to form the microparticles or nanoparticles. The method includes the further steps of preparing a film composition including at least one pre-polymer solution; preparing a suspension comprising the microparticles or nanoparticles and the film composition; loading the suspension into a 3D printer; printing, via the 3D printer, at least one microneedle made from the suspension; and, converting the pre-polymer solution into a cross-linked biopolymer by exposing the at least one microneedle to UV light. Also disclosed are microneedles containing a vaccine for transdermal delivery.

The present disclosure relates to a method of treating or preventing a viral infection by raising the pH of the airways of a subject. The effect can be mediated directly by administering a pharmaceutically acceptable basic solution. Additionally, the method provides co-administering an anti-viral composition to the subject.

The present disclosure relates to a method of treating or preventing a viral infection by raising the pH of the airways of a subject. The effect can be mediated directly by administering a pharmaceutically acceptable basic solution. Additionally, the method provides co-administering an anti-viral composition to the subject.

The present disclosure provides methadone prodrugs, pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a methadone prodrug that provides enzymatically-controlled release of methadone, and an optional enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of methadone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.

The present disclosure provides methadone prodrugs, pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a methadone prodrug that provides enzymatically-controlled release of methadone, and an optional enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of methadone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.